PubMed Health⌕ Search

Biomedical subjects

E Himmrich

Publications and source records attributed to E Himmrich.

At least 19 recordsLinked to original sources
PubMed2000

[Where should the implantable ECG event recorder be placed?].

Aim of our study was the comparison of bipolar ECG quality (with a 4 cm lead distance) at different sites within the anterior thorax to find the preferable implantation site for an ECG event recorder (ECG-ER). In 70 patients a bipolar ECG with a short electrode distance and in the vertical position was registered at the following sites: left and right subclavicular, left and right parasternal (4th-5th ICR), left and right anterior axilla (4th-5th ICR), at the heart apex and subxiphoidal. Then it was compared to the standard lead II. In 34 patients, an additional comparison between vertical and horizontal ECG registration was performed at the above mentioned sites. During implantation of an ECG-ER in 5 patients, ECG signals were compared with electrodes placed towards the skin or towards the muscle. The best ECG quality (greatest QRS amplitude, visible P-wave and pacemaker spike, measurable QT period and bundle-branch block) and the best agreement with standard lead II was found in 67% left parasternal, significant less often (p < 0.001) right parasternal (14.3%), left subclavicular (7.1%), apical (5.7%), and subxiphoidal (4.3%). In a vertical electrode position a significantly higher QRS amplitude and a more often visible P wave was found in comparison to a horizontal electrode position. In all cases, there was good agreement between bipolar surface ECG at the implantation site and ECG-ER stored signals. When the ECG-ER is positioned with electrodes towards the muscle, significant noise-signal occurred in all 5 patients. Only in 3 patients was a P wave visible, but with a slightly greater QRS amplitude than in ECG-ERs positioned with electrodes towards the skin. From these results, it is recommended to implant ECG-ERs vertically with electrodes towards the skin and in the parasternal position.

Adult↗
PubMed2000

[Hidden intracardiac conduction disturbances and their spontaneous course in patients with progressive muscular dystrophy].

In patients with progressive muscular dystrophy (PMD) invasive electrophysiologic studies can detect hidden intracardiac conduction disturbances. The aim of this study was a long-term follow-up of these patients. Twelve consecutive patients (9 m, 3 f, age 28 +/- 4 yrs) without cardiac symptoms and with normal echocardiographic findings were included in the study. They suffered from different stages of PMD type Erb (n = 4), Becker-Kiener (n = 4), Duchenne (n = 2) and Landouzy-Déjerine (n = 2). At the beginning of the study all patients underwent an invasive electrophysiologic study (EPS). The follow-up of 5.5 yrs included regular clinical visits, ECGs, and Holter recordings (every 3 months) as well as an echocardiography every 6 months. In 4 patients the EPS revealed a hidden interatrial conduction disturbance (AHRS-ACS 120 +/- 18 ms), and in 10 pts an infrahisian conduction disturbance was found (HV max. 156 +/- 4 ms). Conduction defects were seen independently from the type of PMD and the stage of the disease. During the follow-up the initially hidden interatrial conduction disturbance became evident in the surface ECG in 2 of 4 pts. One of them developed paroxysmal atrial fibrillation. Five of 10 pts with an initially hidden infrahisian conduction disturbance developed an AV block grade I-III and in one case additionally a bundle branch block. Four of these pts--whose PMD showed progression or who developed congestive cardiomyopathy--needed pacemaker implantation because of a first-degree AV block + bifascicular bundle branch block (n = 1), a Mobitz II second-degree AV block (n = 1) or a third-degree AV block (n = 2). None of the pts with normal findings at the EPS showed abnormal p-waves, an AV block, or an intraventricular conduction disturbance during the follow-up. We conclude that intracardiac conduction disturbances, especially infrahisian defects including high-degree AV blocks, are a common finding in pts with PMD. Therefore a regular cardiological screening including an ECG and a Holter recording is reasonable in these patients.

Adolescent↗
PubMed1999

Safety and efficacy of implantable defibrillator therapy with programmed shock energy at twice the augmented step-down defibrillation threshold: results of the prospective, randomized, multicenter Low-Energy Endotak Trial.

Whether the safety and efficacy of implantable cardioverter defibrillator (ICD) therapy can be assured with lower output devices is an important question. The purpose of this study was to evaluate whether programming the device output at twice the augmented defibrillation threshold was as safe and effective as using the maximum energy. Patients indicated for ICD therapy, but without slow monomorphic ventricular tachycardia (MVT), who achieved an augmented defibrillation threshold (DFT plus) < or = 15 joules (J) with a single endocardial lead system and a biphasic defibrillator were included in the study. Prior to ICD implantation, patients were randomized into 2 groups. The shock energies in test group patient were set as follows: first shock at twice DFT plus, the second to fifth shocks at maximum output (34 J). In control group patients, all shocks were programmed at 34 J. The study population consisted of 166 consecutive patients (mean age 57.4 +/- 12.1 years, mean left ventricular ejection fraction 36.8 +/- 13.8%). Mean DFT plus was 9.6 +/- 3.2 J in test group patients and 10.1 +/- 3.5 J in control group patients (p = 0.36). During a mean follow-up of 24.2 +/- 9.6 months, 736 arrhythmia episodes were analyzed. The first shock efficacy was 98.3% in the test group patients versus 97.4% in the control group (p = 0.45). Total mortality was 6%, equally distributed in both study groups. The results of this study prove that the method of doubling the defibrillation energy at the DFT plus level provides an adequate safety margin in defibrillator therapy.

Adult↗
PubMed1999

[Is ICD-programming for double intraoperative defibrillation threshold energy safe and effective during long-time follow-up? Results of a prospective randomized multicenter study (Low-Energy Endotak Trial--LEET)].

The aim of this prospective and randomized study was to evaluate the safety and efficacy of a reduced shock strength in transvenous implantable defibrillator therapy. So far clinical data concerning the safety margin of the shock energy in ICD therapy do not exist. The shock energy tested during long-term follow-up in this study was twice the intraoperatively measured defibrillation threshold (DFT). A total number of 176 consecutive patients representing a typical cohort of ICD patients were evaluated. All patients received a non-thoracotomy lead system (CPI, Endotak 0070, 0090) and a biphasic cardioverter-defibrillator with the ability to store episodes (Cardiac Pacemakers Inc., Ventac TM PRx II, PRx III). The intraoperative defibrillation threshold (DFT) was evaluated in a step-down protocol (15, 10, 8, 5 J) and had to be < or = 15 J for inclusion into the study. The lowest effective energy terminating induced ventricular fibrillation had to be confirmed and was defined as DFT+ augmented defibrillation threshold. The DFT+ value was tested immediately after successful implantation, at discharge, and after a follow-up period of one year. Prior to implantation the patients were randomized into two groups. The energy of the first shock in the study group was programmed at twice DFT+ and in the control group at the maximum energy output (34 J). The efficacy of the first shock and its reproducibility in DFT testings and in spontaneous episodes during long-term follow-up of the study group were compared to those in the control group. A DFT+ value was found to be < or = 15 J in 166 of 176 patients (94%). The DFT+ in the study group was 9.6 +/- 3.2; in control group 10.1 +/- 3.5 J. The prohability of successful defibrillation at DFT+ level after one year was 84%. The success rate of the first shock meant to terminate induced ventricular fibrillation (VF) was 99.5% in the study group (217 of 218 episodes) and 99% in the control group (201 of 203 episodes). During follow-up of 24 +/- 9 months spontaneous episodes in the study group, 83/86 (96.5%) monomorphic ventricular tachycardias (MVT) and 38/40 (95%) VF-episodes were converted successfully by the 2x DFT+ shock. In the control group the first shock was successful in 151/156 (96.8%) spontaneous MVTs and in 30/33 (91%) VF episodes. The efficacy of the first shock was not influenced by clinical data such as the underlying cardiac disease, left ventricular function, ongoing antiarrhythmic therapy with amiodarone, or the number of spontaneous episodes per day or by the DFT itself. At a mean follow-up of two years there was no significant difference between the two groups concerning the incidence of sudden cardiac death (2.4% in the study group vs. 3.8% in the control group). In conclusion programming the first shock with the ICD lead system used in this study at 2x DFT+ is as efficient as a shock energy of 34 J in order to terminate induced and spontaneous episodes of VT/VF. Thus, the safety of ICD-therapy is not impaired when programming the shock energy at the 2x DFT+ value.

Defibrillators, Implantable↗
PubMed1998

[Prognostic significance of analysis of heart rate variability inpatients with dilated cardiomyopathy].

UNLABELLED: Sudden cardiac death is frequent in patients with dilated cardiomyopathy. To assess the risk of an arrhythmic event is still difficult. Here the analysis of the heart rate variability offers new possibilities. METHOD: 25 patients (18 males, 7 females, age 53 +/- 9 yrs) with dilated cardiomyopathy were included in the study. Analysis of heart rate variability assessed by time- and frequency-domain measures was determined from Holter recording. The mean follow-up was 18 +/- 5 months. RESULTS: 6 patients died (5 of sudden cardiac death, 1 of heart failure), 1 patient with an implanted defibrillator received an adequate shock. Parameters influenced by low- and mid-frequent oscillations of the heart rate were significantly lower in patients who died suddenly or had adequate shocks. The best predictive parameter was the s.d.RR: all patients with an s.d.RR < 50 ms had lethal arrhythmias whereas the s.d.RR of the surviving patients was > or = 50 ms. No significant difference was found or high frequency parameters, which are mainly influenced by parasympathetic activity. CONCLUSION: The analysis of heart rate variability is of prognostic relevance in patients with dilated cardiomyopathy. Especially the s.d.RR is able to identify patients with a high risk of a sudden cardiac death.

Adult↗
PubMed1998

[Reproducibility of the effectiveness of defibrillation for terminating induced ventricular fibrillation using intraoperatively measured defibrillation threshold energy in patients with implanted cardioverter-defibrillator].

The aim of the present study was to assess the long-term reproducibility of the defibrillation efficacy of energies set at the intraoperatively measured defibrillation threshold using a modified testing protocol. Between December 1993 and January 1996, 83 patients receiving an implantable cardioverter-defibrillator (ICD) in combination with a non-thoracotomy lead system and having an intraoperatively measured defibrillation threshold (DFT) < or = 15 J were enrolled in a substudy of a prospective, randomized multicenter trial ("Low Energy Endotak Trial" (LEET)). Step-down DFT testing was performed intraoperatively (15, 10, 8, 5 J). It was mandatory to reproduce a successful conversion of ventricular fibrillation at the DFT energy during implantation (DFT+). At the end of implantation, at predischarge, and after one year, assessment of the defibrillation efficacy of DFT+ energy was repeated (first shock: DFT+, second shock: 2 x DFT+). Mean DFT+ at implant was 9.6 + 3.3 J. Immediately after implantation, successful conversion of induced ventricular fibrillation was achieved in 70/79 (89%) patients using DFT+ energies. In 7/8 (89%) patients only the second shock set at 2 x DFT+ and in one patient only the third shock set at maximum energy (34 J) was successful. At predischarge, defibrillation efficacy of DFT+ was reproducible in 61/77 (79%) patients. The remaining 16 patients were successfully converted using a second shock set at 2 x DFT+. One year after implantation, conversion of ventricular fibrillation was achieved at energies set at DFT+ in 52/62 (84%) patients and in the remaining 10 patients at energies set at 2 x DFT+. A total of 183/218 (84%) episodes of induced ventricular fibrillation were terminated successfully using DFT+ energies. There was no correlation between the intraoperatively determined DFT+ or the underlying cardiac disease and the defibrillation efficacy. These results demonstrate that the defibrillation efficacy for termination of induced ventricular fibrillation using DFT+ energies is reproducible at implantation, at predischarge, and one year after ICD insertion. Energies set at twice DFT+ seems to allow for reliable defibrillation within the first year after ICD implantation.

Adult↗
PubMed1998

Paroxysmal atrial fibrillation and high degree AV block: use of single-lead VDDR pacing with mode switching.

Dual chamber rate responsive pacing incorporating a mode switching option is increasingly used in patients with chronic paroxysmal atrial fibrillation and high degree AV block. Single-lead VDDR pacemakers have rarely used for this indication. The purpose of this study was to determine their reliability of atrial sensing during atrial fibrillation, the percentage of atrial synchronous ventricular pacing, and the behavior of the sinus rate outside the phases of atrial fibrillation. We studied ten patients with a single-lead VDDR pacemaker implanted for this indication. Follow-up visits were performed at predischarge and after 1, 3, 6, 12, 18, and 24 months. During the mean follow-up period of 18.9 +/- 6.9 months, the atrial sensing thresholds in sinus rhythm remained stable. Atrial synchronous ventricular stimulation was achieved in 68.7 +/- 31.2% (median 82.5%) of the whole follow-up time. All patients showed an adequate atrial rate response during sinus rhythm. Atrial fibrillation was detected by the pacemakers in 24.0 +/- 29.8% of time. In 3 of 10 patients the duration of atrial fibrillation showed a steady increase from visit to visit. The sensed amplitudes of atrial fibrillation ranged from 0.1-1.0 mV. A programmed atrial sensitivity of 0.1 mV was necessary to achieve complete sensing of atrial fibrillation. None of the patients experienced tachycardias with optimized pacemaker programming. Single-lead VDDR pacing incorporating a mode-switching option is useful in patients with high degree AV block and paroxysmal atrial fibrillation, since it provides atrial synchronous ventricular pacing in more than two-thirds of follow-up time. In a subgroup of patients, a progressive increase of the time during atrial fibrillation was demonstrated. A reliable detection of paroxysmal atrial fibrillation requires the programming of the atrial sensitivity to its most sensitive value.

Atrial Fibrillation↗
PubMed1998

Pacemaker therapy in premature children with high degree AV block.

The smallest pacemaker pulse generator and a steroid-eluting bipolar epicardial lead were implanted in two premature children with symptomatic AV block. Stable capture threshold and high amplitude evoked response electrogram resulted in normal function of the pacemaker Autocapture algorithm, which adjusts output 0.3 V above the measured capture threshold. Autocapture had previously been used only with endocardial leads. Longer-term observation is required.

Electrodes, Implanted↗
PubMed1998

How reliable is atrial sensing in single-lead VDD pacing: comparison of three systems.

UNLABELLED: This study evaluated the reliability of atrial sensing, expressed as AV synchronous stimulation, in three VDD systems with the atrial sensitivity (AS) programmed to a conventional value with a 2:1 safety margin compared to most-sensitive values. We studied 34 sex- and age-matched patients with 3 VDD systems: 14 with Unity 292-07, 10 with Saphir 600, and 10 with Thera VDD (5 model 8948 and 5 model 8968i). Two 24-hour Holters were performed on consecutive days. The AS was programmed in a randomized order to its most-sensitive value or to a 2:1 safety margin. All other parameters were programmed identically. The patients underwent a myopotential oversensing test and a daily life activity protocol. A beat-to-beat analysis of the Holters was performed to determine AV synchrony. For the entire group AV synchrony with conventional AS was 98.63% +/- 2.57%, compared to 99.80% +/- 0.43% with most-sensitive values (p = 0.002). There was no difference between the three systems with conventional AS. With the most-sensitive AS, AV synchrony was: Unity 99.99% +/- 0.03%, Saphir 99.42% +/- 0.60% (P = 0.002), Thera 99.81% +/- 0.35% (ns). In the Saphir system with an atrial blanking period of 150 ms, ventricular far-field sensing could be demonstrated in 5 of 10 patients. This reduced the percentage of AV synchrony due to an unwanted mode-switch to a nontracking mode. Myopotential oversensing was not detected in any patient. CONCLUSION: The VDD systems tested under identical conditions showed reliable P wave sensing at the most-sensitive atrial sensing setting without myopotential oversensing. Ventricular far-field sensing reduced AV synchrony and must be avoided by appropriate refractory periods.

Aged↗
PubMed1998

First experience with an automatic sensing algorithm in single-lead VDD stimulation.

UNLABELLED: An "Autosensing" algorithm available in SSI(R) and DDR(R) pacemakers automatically adapts the device's sensitivity to changing intracardiac signals. The atrial sensing function of this algorithm was tested for the first time with a VDD pacing system in which large variations of the atrial signal may occur because the atrial electrodes float in the atrial blood pool. METHODS: 15 patients with a VDD pacing system were studied (Unity 292-07, lead 425; Sulzer Intermedics). The atrial sensing threshold was measured, and the atrial sensitivity was programmed with a 2:1 safety margin. The autosensing algorithm and sensitivity profile were temporarily activated, and an ambulatory ECG with continuous marker annotation was recorded. All patients underwent a 30-minute daily life activities protocol. A beat-to-beat analysis of the ambulatory ECG was correlated with the changes in atrial sensitivity. RESULTS: The algorithm changed the baseline sensitivity from 0.57 +/- 0.23 mV during the test to 0.39 +/- 0.20 mV after the final rest period (P < 0.05). During the test 12.6 +/- 10.2 adaptations of the sensitivity occurred (range 0-33). In eight patients atrial undersensing occurred in 4.4% +/- 7.5% of the cycles (4-458 unsensed P waves). In these patients, the algorithm continuously adjusted the sensitivity towards more sensitive values, operating 19.1 +/- 18.3 changes compared with 5.4 +/- 7.3 changes in patients without undersensing (P = 0.009). Oversensing did not occur. CONCLUSION: The autosensing algorithm effectively optimized atrial sensitivity in VDD pacing. In patients with atrial undersensing the algorithm continuously remained near the most sensitive settings, thus reacting as intended. A faster sensitivity adjustment of the system would be desirable.

Activities of Daily Living↗
PubMed1997

Feasibility and sensing thresholds of temporary single-lead VDD pacing in intensive care.

Long-term pacemaker treatment of patients with a high-degree atrioventricular (AV) block routinely uses AV synchronous pacing because of its hemodynamic advantages compared with VVI pacing. In cases of temporary pacing, however, the limitations inherent in attempting to reliably position a temporary atrial lead generally influences the use of VVI pacing. We therefore tested the use of temporary single-lead VDD pacing, making AV pacing possible with only 1 lead, in 22 patients requiring temporary pacing due to a high-degree AV block. AV synchronous stimulation was achieved in all patients using a quadripolar lead with an atrial dipole with the atrial rings spaced 30 mm apart. During follow-up (14.1 +/- 12.5 hours) intermittent undersensing was detected in 4 of the 22 patients. We initially evaluated the atrial sensing threshold by decreasing the pacemaker device sensitivity stepwise in all patients (1.54 +/- 1.08 mV; n = 22). In 15 patients an intra-atrial electrocardiogram was recorded. During the breathing cycle, the maximum P-wave amplitude was significantly different from the minimum P-wave amplitude (2.19 +/- 1.00 mV vs 1.25 +/- 0.65 mV, p < 0.005). The atrial signal detected by the single lead was further analyzed in 10 of 15 patients using various filters. A mean signal loss of 45% was observed, increasing the lower bandpass frequency from 0.1 to 40 Hz (1.73 +/- 0.71 mV vs 0.92 +/- 0.51 mV, p < 0.02). Lowering the upper filter range from 1,000 Hz down to 100 Hz did not significantly influence the atrial signal (1.73 +/- 0.71 mV vs 1.61 +/- 0.75 mV, NS). Single-lead VDD pacing, even on a temporary basis, is a reliable means of achieving AV synchronous pacing. Due to the floating atrial dipole, the system is characterized by a high degree of variability in the atrial signal with intermittent lower values. A significant signal loss must be expected when a lower bandpass frequency of 40 Hz is used.

Aged↗
PubMed1997

[Late potentials in the diagnosis of post-infarction patients: arrhythmogenic risk and clinical symptomatology].

A prospective study was performed of the correlation of ventricular late potentials (LP) and clinical parameters in patients after acute myocardial infarction. To evaluate the prognostic significance of the signal-averaged-electrocardiogram (SAECG) in risk stratification of sudden cardiac death and arrhythmogenic events, the clinical characteristics of these post-infarction patients were performed in a follow-up-period. 243 consecutive patients underwent SAECG for detection of late potentials in the second week after acute myocardial infarction. After a mean follow-up of 9 months the patients were asked a standardized questionnaire. Late potentials are independent of age, sex, left ventricular ejection fraction, peak activity of MB fraction of creatine kinase, and the cardiovascular risk factors in postinfarction patients. In patients, who received thrombolytic therapy, the incidence of late potentials is lower (p < 0.05) and in patients with posterior wall infarction it is significantly higher (p < 0.04). In the follow-up period patients with abnormal SAECG show a significantly higher rate of angina pectoris, palpitations, dizziness, and syncope. By way of contrast, postinfarction patients with normal SAECG feel mainly comfortable in the follow-up (p < 0.01). The mortality was even in both groups. Sudden cardiac death in the late postinfarction period shows a significant correlation with the finding of late potentials in SAECG in the early myocardial infarction period (p < 0.01). The SAECG for detection of late potentials as a non-invasive investigation in the early postinfarction period characterizes patients with an arrhythmogenic risk, especially sudden cardiac death, independent of other conventional methods. Furthermore, the impaired patient with clinical symptoms in the late postinfarction period is hereby identified.

Action Potentials↗
PubMed1997

Implantable cardioverter-defibrillator therapy: influence of left ventricular function on long-term results.

The degree of left ventricular impairment in an acknowledged important prognostic marker of long-term outcome for patients being evaluated for implantation of cardioverter-defibrillators. Just how left ventricular function impacts freedom from all-cause mortality, as well as from sudden death and cardiac death, is a subject of current major debate, and is analyzed hereunder from a large, recent multicenter ICD patient cohort. The multicenter database consists of data from 361 patients receiving implantable cardioverter-defibrillators for standard indications, that is, documented episodes of ventricular fibrillation or sustained ventricular tachycardias with poor hemodynamic toleration. Data were collected from 1988 to 1995 at three centers in Germany. Two-hundred and three patients (56%) had a left ventricular ejection fraction (LVEF) > 0.30 (group I), and 158 patients (44%) had a LVEF < or = 0.30 respectively (group II). The mean follow-up was 23.9 months (range 3-98 months). Overall survival at 5 years for group II patients was lower, as expected, at 74.1% versus 94.2%, respectively (P < 0.0001). Mortality was higher for each different cause of death in group II patients than in Group I: sudden arrhythmic deaths, 5 versus 1 (P < 0.048); nonsudden cardiac deaths, 16 versus 5 (P < 0.002); noncardiac deaths, 7 versus 2 (P < 0.03). Group II patients received a higher rate of at least one presumably appropriate shock at 86 (54.4%) versus 89 (43.8%) in group I (P < 0.05). However (and somewhat surprisingly), neither the time from ICD implantation to death, comparing only the patients who died, nor the event-free probability of appropriate shocks due to very rapid, sustained ventricular arrhythmias (> 230 beats/min), including a presumed risk of sudden arrhythmogenic death, differed between groups I and II. Sudden cardiac death was only marginally affected by LVEF (group I, 1.5% actuarial, 5-year survival 99.5%; group II, 3.1% and 95.8%, respectively). Therefore, the lower overall survival in ICD patients with LVEF < or = 0.30 resulted mainly from causes of death that cannot be directly influenced by cardioverter-defibrillator therapy. However, because group II patients had a far higher incidence of at least one ventricular tachyarrhythmia terminated by ICD shocks than group I patients, they also probably derived benefit from ICD therapy.

Cohort Studies↗
PubMed1996

Is there a risk for interaction between mobile phones and single lead VDD pacemakers?

Mobile phones may cause pacemaker interference. Patients with a single lead VDD pacemaker might be at special risk, since the atrial sensitivity is often programmed to low (high sensitivity) threshold values and the majority of patients are pacemaker dependent due to the underlying high degree AV block. We evaluated 31 patients with three types of single lead VDD pacemakers: 12 Unity, 292-07 (Intermedics, Inc.); 10 Thera VDD, 8948 or 8968i (Medtronic, Inc.); and 9 Saphir 600 (Vitatron, Inc.) for interference from a cellular mobile phone with a power of 2 W (D-net). For this purpose, atrial and ventricular sensitivity settings were programmed to their most sensitive values (A: 0.1-0.25 mV; V: 1.0 mV) and ventricular sensing was programmed to unipolar. With the ECG continuously monitored, the phone's extendable antenna was brought in direct contact with the patient's skin at the right sternal border, with the tip of the antenna in skin contact just below the clavicle, within 5 cm of the pacemaker connector. Then multiple phases of phone calls were performed, and the effects on the pacemakers recorded. In our group of patients with three different types of single lead VDD pacemakers, no interference could be detected using a 2-W mobile phone in the digital D-net. The programmed values remained unchanged after the interference test. Therefore, the risk of interference seems to be low for the VDD pacemakers tested, although our study design does not allow to entirely exclude the possibility of interference from a mobile phone.

Cardiac Pacing, Artificial↗
PubMed1996

Holter recordings with continuous marker annotations: a new tool in pacemaker diagnostics.

UNLABELLED: Pacemakers provide marker annotations to facilitate the interpretation of pacemaker electrocardiograms (ECGs) and can be used in cases of suspected pacemaker malfunction or to understand pacemaker behavior. Due to the need for a programmer, only short-term evaluations are possible. We evaluated a prototype Telemetry Data Logger (TDL) designed to continuously transfer markers from the pacemaker to a conventional Holter recorder. A miniaturized telemetry receiving coil was attached to patient's skin above the pacemaker, which was programmed to transmit markers continuously. The TDL, which receives and converts markers into eight positive and eight negative deflections, ranging from -2.5 to +2.5 mV in amplitude, was connected to one channel of a conventional Holter recorder (Tracker 2). We performed 20 Holters in 13 patients who had implanted VDDR or DDDR devices from the same manufacturer and evaluated three versions of software. Marker transmission was possible in all patients, producing Holter ECGs with complete marker annotations. Artifacts occurred < 4% of the time. A 50-ms rectangular pulse was optimal for marker interpretation. The device, which was easy to use and well accepted by the patients, assisted in the diagnosis of inappropriate pacemaker programming, even when the surface ECG seemed to show regular pacemaker function. In the presence of low quality surface ECGs, marker annotations allowed the assessment of pacemaker function. The capability to annotate the onset of special algorithms, like tachycardia termination algorithms or mode switching, facilitates interpretation of pacemaker behavior, enabling a reliable assessment of the appropriateness of such algorithms. CONCLUSION: The TDL effectively enables pacemaker markers to be inscribed onto a conventional Holter recording, facilitating the interpretation of pacemaker ECGs and the diagnosis of inappropriate pacemaker programming even when not discernible from the surface ECG alone.

Algorithms↗
PubMed1996

A simple method for preoperative assessment of the best fitting electrode length in single lead VDD pacing.

For single lead VDD pacing, electrodes with various distances between the lead tip and the floating atrial dipole (AV distance) are available. Using different AV distances allows positioning of the atrial dipole in the mid- to high right atrium, regardless of the size of the right heart. In this position, reliable atrial sensing and rejection of ventricular far-field potentials can be expected. A simple test for the preoperative assessment of the best fitting AV distance in the individual patient was tested. We studied 24 consecutive patients prior to implantation of a VDD pacemaker. With the patient in supine position, a test electrode with an AV distance of 13 cm was taped onto the thorax. Under fluoroscopic control, it was moved until its course and projection onto the heart was equal to that of a ventricular lead. If fluoroscopy then showed a projection of the atrial dipole onto the mid- to high right atrium, a lead with a similar AV distance of 13 or 13.5 cm was used for implantation. If the atrial dipole projected itself too high or too low, a shorter or longer lead had to be implanted. The maximum time for the test was 2 minutes, and the maximum fluoroscopy time was 15 seconds. According to the test, a lead with an AV distance of 13 or 13.5 cm was implanted in 18 of 24 patients, and a lead with an AV distance of 15.5 or 16 cm was implanted in 6 of 24 patients. The atrial dipole could easily be positioned in the mid- to high right atrium in all patients, demonstrating a correct preoperative assessment of the best fitting AV distance. Intraoperatively, a P wave amplitude of 3.5 +/- 3.0 mV was measured. The described test allows a fast and reliable assessment of the best fitting electrode length in single lead VDD pacing.

Adult↗
PubMed1996

[DDD versus DDDR pacemaker stimulation: comparison of cardiopulmonary performance, incidence of atrial arrhythmias and quality of life].

The purpose of this study was to assess cardiopulmonary exercise capacity, variation in heart rate during everyday activities, frequency of atrial arrhythmias and quality-of-life during accelerometer-based rate modulated dual-chamber pacing. Nine chronotropically incompetent and 14 chronotropically competent patients (mean age 51 years) were randomly assigned to DDD and DDDR mode and evaluated by a semisupine bicycle exercise testing exceeding the anaerobic threshold, 24-h Holter monitoring and a quality-of-life questionnaire. In the subgroup of patients with chronotropic incompetence, defined by a HR/VO2-ration, 2 beats/ml/kg, during DDDR pacing, compared to DDD, maximum heart rate increased from 83 +/- 13 to 132 +/- 7 beats/min (p < 0.01), maximum oxygen uptake from 12.7 +/- 3.1 to 15.3 +/- 3.2 ml/kg/min ( p < 0.05) and the VO2/WR-ratio from 8.1 +/- 1.0 to 9.0 +/- 0.9 ml/min/watts (p < 0.05). Exercise duration lengthened from 252 +/- 59 to 301 +/- 96 s (p < 0.05). During the 24-h Holter recordings the average maximum heart rate rose form 69 +/- 7 in the DDD mode to 78 +/- 9 beats/min in the DDDR mode significantly (p < 0.05). DDDR pacing did not result in an increased number of atrial salvos (2.6 atrial events/24 h) when compared to DDD pacing (2.5 atrial events/24 h, N.S.). These objective results were confirmed by the quality-of life assessment due to a symptom questionnaire. The symptom score declined from 20 +/- 10 in the DDD mode to 16 +/- 7 in the DDDR mode (p < 0.01). In the patients with chronotropic competence, however, cardiopulmonary exercise capacity did not improve in the DDDR mode: maximum heart rate was 120 +/- 21 versus 130 +/- 24 beats/min (N.S.), maximum oxygen uptake 17.7 +/- 5.9 versus 16.8 +/- 5.9 ml/kg/min (N.S.), The VO2/WR-ratio 9.8 +/- 2.3 versus 9.2 +/- 2.5 ml/min/watts (N.S.) and the exercise duration 407 +/- 159 versus 406 +/- 165 s (N.S.). The average maximum heart rate was 80 +/- 15 in the DDD mode and 83 +/- 16 beats/min in the DDDR mode (N.S.). Significantly more atrial arrhythmias occurred in the DDDR pacing mode: 1.6 atrial salvos per 24 h in the DDD mode versus 4.8 atrial salvos per 24 h in the DDDR mode (p < 0.05). This patient subgroup experienced a significant worsening of his quality-of-life. The symptom score rose from 20 +/- 9 in the DDD mode to 28 +/- 11 in the DDDR mode (p < 0.05). In conclusion, DDDR pacing improved cardiopulmonary exercise capacity, normalized heart rate variation over 24 h and increased quality-of-life in patients with chronotropic incompetence. On the contrary, since the DDDR pacing more could not improve cardiopulmonary exercise capacity, increased atrial arrhythmias and worsened the patient's quality-of-life, patients with chronotropic competence should not be programmed in the DDDR pacing mode.

Adolescent↗